Pradžia › Vilkligės nefritas › Koloradas
Vilkligės nefritas klinikiniai tyrimai Koloradas
7 tyrimai dėl Vilkligės nefritas ieško dalyvių vietose Koloradas.
Miestai Koloradas
Oficialus tyrimo tekstas (anglų kalba)
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
- University of Colorado Denver, Aurora
Renkami dalyviai2 fazė
Amžius nuo 18 iki 100 · Visoms lytims · Atnaujinta 2026-10-01 · NCT05268289VIBRANT: VIB4920 for Active Lupus Nephritis
- University of Colorado School of Medicine: Division of Rheumatology, Aurora
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-16 · NCT05201469The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
- Children's Hospital Colorado, Aurora
Renkami dalyviai2 fazė
Amžius nuo 8 iki 20 · Visoms lytims · Atnaujinta 2026-09-14 · NCT05538208A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- University of Colorado Denver, Aurora
Renkami dalyviai1 fazė
Amžius nuo 18 iki 74 · Visoms lytims · Atnaujinta 2026-09-10 · NCT07085104A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
- Children's Hospital Colorado, Anchutz Medical Campus, Aurora
Renkami dalyviai2 fazė
Amžius nuo 5 iki 17 · Visoms lytims · Atnaujinta 2026-09-03 · NCT05039619PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
- Western Nephrology & Metabolic Bone Disease, PC, Arvada
Renkami dalyviai4 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-08-03 · NCT07611214A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
- University of Colorado, Denver, Denver
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-02-11 · NCT07403188Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.